Introduction: This poster presentations reports on preliminary findings of a small-scale rurally-located study. This study aimed to explore the influence of demographic and clinical factors, as well as genetic mutations, on lung cancer patient survival among a patient population.
Methods: We conducted a retrospective study including 99 patients with different lung cancer types and stages, located in a rural area. Treatment options such as immunotherapy, chemotherapy, and radiotherapy, with or without combinations, were analyzed. We investigated the effect of factors like gender, Charlson Comorbidity Index (CCI) scores, postal code, cancer stage, treatment type, complications, and genetic mutations (EGFR, ALK, ROS-1, PDL-1, and KRAS) on survival.
Results: Significant differences in survival were observed based on gender and CCI scores, with female patients surviving longer and lower CCI scores linked to increased survival times. No significant associations were found between survival and postal code, cancer stage, treatment type, or complications. PDL-1 status significantly affected lung cancer type but not survival, while other genetic mutations showed no significant influence on survival, cancer stage, or comorbidities.
Discussion & Conclusion: Our study underlines the impact of gender and comorbidity on lung cancer patient survival and emphasizes the importance of considering these factors in clinical decision-making and future research. Further investigation of genetic mutations' effect on survival in larger cohorts is needed to provide stronger evidence for personalized treatment strategies, and to understand the potential of such approaches in rural patient cohorts.